Survey on schizophrenia treatment in Mexico: Perception and antipsychotic prescription patterns

BMC Psychiatry

Volumn 4, Issue , 2004, Pages

  Apiquian, Rogelio ^a   Fresán, Ana ^a   de la Fuente Sandoval, Camilo ^a   Ulloa, Rosa Elena ^c   Nicolini, Humberto ^b,d  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b Grupo Medico Carracci   (Mexico)

^c Hospital Psiquiatrico Infantil Dr Juan N Navarro   (Mexico)

^d Lab of Comparative Neurophysiology   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; ZIPRASIDONE;

AKATHISIA; ARTICLE; AWARENESS; CLINICAL STUDY; COGNITIVE DEFECT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; ECONOMIC ASPECT; EXTRAPYRAMIDAL SYMPTOM; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MENTAL HEALTH CENTER; MEXICO; NEGATIVE SYNDROME; PHYSICIAN ATTITUDE; POSITIVE SYNDROME; POSTAL MAIL; PRESCRIPTION; PRIVATE PRACTICE; PSYCHIATRIST; QUESTIONNAIRE; SCHIZOPHRENIA; STANDARDIZATION; TARDIVE DYSKINESIA; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG UTILIZATION; HALOPERIDOL; HEALTH CARE SURVEYS; HUMANS; MEXICO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRY; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS;

EID: 2942571214     PISSN: 1471244X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-244X-4-12     Document Type: Article

References (57)

1. Deniker P: Psychopharmacology and biologic psychiatry. Historical review. Soins Psychiatrie 1983; 37:5-6
2. Hippius H: A historical perspective of clozapine. J Clin Psychiatry 1999; 60(Suppl 12):22-23
3. Treatment of schizophrenia. The Expert Consensus Panel for Schizophrenia. J Clin Psychiatry 1996; 57(Suppl 12B):3-58
4. Canadian clinical practice guidelines for the treatment of schizophrenia. The Canadian Psychiatric Association. Can J Psychiatry 1998; 43(Suppl 2):25S-40S
5. Treatment of Schizophrenia. 1999. The Expert Consensus Guideline Series. J Clin Psychiatry. 1999; 60(Suppl 11):3-80
6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl):1-56
7. Stip E: Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry & Neurosci 2000; 25(2):137-153
8. Keefe RS, Silva SG, Perkins DO, Lieberman JA: The effects of atypical antipsychotics drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25(2):201-222
9. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280(1):83-97
10. Stahl SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62(11):841-842
11. Apiquian R, Ulloa RE, Fresán A, Loyzaga C, Nicolini H, Kapur S: Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. Schizophr Res 2003; 59(1):35-39
12. Josefson D: Marketing of antipsychotic drugs attacked. BMJ 1998; 316(7132):648
13. Angell M: Is academic medicine for sale? N Engl J Med 2000; 342(20):1516-1518
14. Cho MK, Bero LA: The quality of drug studies in symposium proceedings. Ann Intern Med 1996; 124(5):485-489
15. Mandelkern M: Manufacturer support and outcome. J Clin Psychiatry 1999; 60(2):122
16. Safer DJ: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190(9):583-592
17. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29(1):15-31
18. Rabinowitz J, Lichtenberg P, Kaplan Z: Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000; 46(2-3):91-96
19. Beasley CMJ, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14(2):111-123
20. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CMJ: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172:499-505
21. Kopala LC: Clinical experience in developing treatment regimens with novel antipsychotic risperidone. Int Clin Psychopharmacol 1997; 12(Suppl 4):S11-S18
22. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58(12):538-546
23. Arvanitis LA, Miller BG, Group. STS: Multiple fixed doses of "Seroquel" (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997; 42(4):233-246
24. Buchanan R, Breier A, Kirkpatrick B, Ball P, Carpenter WJ: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155(6):751-760
25. Copolov DL, Link CGG, Kowalcyk B: A multicentre, doubleblind, randomized comparison of quetiapine (ICI 204,636, "Seroquel') and haloperidol in schizophrenia. Psychol Med 2000; 30(1):95-105
26. Emsley RA, Raniwalla J, Bailey PJ, Jones AM: A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15(3):121-131
27. Fleischhacker W: Clozapine: A comparison with other novel antipsychotics. J Clin Psychiatry 1999; 60(Suppl 12):30-34
28. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156(7):990-999
29. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58(10):965-972
30. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54(6):549-557
31. Baldessarini RJ, Cohen BM, Teicher M: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45(1):79-91
32. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48(8):739-745
33. Oosthuizen P, Emsley RA, Turner J, Keyter N: Determining the optimal dose of haloperidol in first-episode psychosis. J Psychopharmacol 2001; 15(4):251-255
34. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J: Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995; 152(8):1210-1212
35. Van Putten T, Marder SR, Mintz JA: A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47(8):754-758
36. Zhang-Wong J, Zipursky RB, Beiser M, Bean G: Optimal haloperidol dosage for first-episode psychosis. Can J Psychiatry 1999; 44(2):164-167
37. Daskalakis Z, Christensen B, Zipursky RB, Zhang-Wong J, Beiser M: Relationship between D2 occupancy and prolactin levels in first episode psychosis. Biol Psychiatry 1998; 43:113S
38. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine:Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49(7):538-544
39. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4):514-520
40. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33(4):227-235
41. Schlegel S, Schlosser R, Hiemke C, Nickel O, Bockisch A, Hahn K: Prolactin plasma levels and D2 dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl) 1996; 124(3):285-287
42. Ortega-Soto HA, Páez F, Fernández A, Pinedo H, Hernández C: El efecto terapéutico de las dosis umbrales de haloperidol: resultados preliminares de un estudio piloto. Anales del Instituto Mexicano de Psiquiatría 1991:30-34
43. Ortega-Soto HA, Brunner E, Apiquian R, De la Torre MP, Pinedo H, Chávez JL, Moreno J, Páez F: Efecto terapéutico de las dosis umbrales de antipsicóticos, in VIII Reunión de Investigación IMP. Mexico City, Mexico, 1993
44. Ortega-Soto H, Brunner E, Apiquian R, Ulloa R, De la Torre M: Typical antipsychotics: the threshold doses strategy, in XXth CINP Congress. Collegium Internationale Neuro-Psychopharmacologicum. Melbourne, Australia, 1996
45. Kopala LC, Good KP, Fredrikson D, Whitehorn D, Lazier L, Honer WG: Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs. International Journal of Psychiatry in Clinical Practice 1998; 2(Suppl 19):S19-S26
46. Keshavan MS, Schooler NR, Sweeney JA, Haas GL, Pettegrew JW: Research and treatment strategies in first-episode psychoses: The Pittsburgh experience. Br J Psychiatry 1998; 172(Suppl 33):60-65
47. Apiquian R, Fresán A, Herrera K, Loyzaga C, García-Anaya M, Ulloa RE, García-Marín J, Gutierrez D, Nicolini H: Estudio comparativo de dosis mínimas de haloperidol vs olanzapina en el primer episodio psicótico. Psiquiatría y Salud Integral 2003; 3(2):56-65
48. Apiquian R, Fresán A, Herrera K, Ulloa RE, Loyzaga C, Gutiérrez D, Nicolini H: Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. Int J Neuropsychopharmacol 2003; 6(4):1-6
49. Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, Walker DJ, Roychowdhury SM, Wang H, Tran PV: Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002; 63(7):569-576
50. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L: Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002; 22(1):20-25
51. Mulholland C, Lynch G, King DJ, Cooper SJ: A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003; 17(1):107-112
52. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158(11):1835-1842
53. Johnstone EC, Crow TJ, Frith CD, Owens DGC, Done JD, Baldwin EJ, Charlette A: The Northwick Park functional psychosis study: diagnosis and outcome. Psychol Med 1992; 22(2):331-346
54. Linszen D, Dingemans P, Lenior M: Early intervention and a five year follow up in young adults with short duration of untreated psychosis:ethical implications. Schizophr Res 2001; 51(1):55-61
55. Vázquez-Barquero JL, Cuesta MJ, Herrera-Castanedo S, Lastra I, Herran A, Dunn G: Cantabria First-Episode Schizophrenia Study: Three-year follow-up. Br J Psychiatry 1999; 174:141-149
56. Fresán A, Apiquian R, Loyzaga C, García-Anaya M, Ulloa RE, Nicolini H: Functional recovery in first-episode psychosis. Psiquiatría y Salud Integral 2002; 2(2):40-44
57. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56(3):241-7